Ichthyosis: Clinical Trials

97 trials for Ichthyosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

55 completed, 13 recruiting, 9 terminated, 8 not yet recruiting. 29 Phase 2, 24 Not applicable, 14 Phase 3, 13 Phase 1, 3 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 229Completed 16, Terminated 6, Recruiting 3, Not yet recruiting 2, Active not recruiting 1, Unknown 1
Not applicable24Completed 18, Not yet recruiting 3, Recruiting 2, Unknown 1
Phase 314Completed 6, Recruiting 4, Terminated 2, Active not recruiting 1, Not yet recruiting 1
Phase 113Completed 8, Terminated 2, Not yet recruiting 1, Recruiting 1, Unknown 1
Early Phase 13Completed 1, Enrolling by invitation 1, Recruiting 1
Phase 43Completed 1, Enrolling by invitation 1, Unknown 1

Follow Ichthyosis: new trials by email Literature Review of Ichthyosis trials Research Report on Ichthyosis

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Epidermal Growth Factor Receptor Inhibition for Keratinopathies
Erlotinib - Epidermolytic Ichthyosis, Palmoplantar Keratoderma
Phase 1 / Phase 2Not yet recruitingNorthwestern University442027-07-012026-08-03
Acupuncture Combined With Transcutaneous Electrical Acupoint Stimulation for Constipation-Predominant Irritable Bowel Syndrome With Anxiety State
Acupuncture, Transcutaneous Electrical Acupoint Stimulation, Sham Transcutaneous Electrical Acupoint Stimulation - IBS, Constipation Predominant, Anxiety State
Not applicableNot yet recruitingThe First Affiliated Hospital of Zhejiang Chinese Medical University582026-10-012026-10-28
Patient Study to Evaluate the Safety and Emollient Performance of Doublebase Once in the Treatment of Ichthyosis
Doublebase Once - Ichthyosis
Not applicableNot yet recruitingDermal Laboratories Ltd1002026-09-072026-09-08
Phase III Clinical Trial of Changji'an Capsules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver-Qi Invading Spleen Syndrome)
Chang Ji'an capsule, Chang Ji'an capsule mimic - IBS, Diarrhea Predominant
Phase 3Not yet recruitingBeijing Hospital of Traditional Chinese Medicine6362026-05-312026-05-28
Study of Skin and Gut Microbiome in a Skin Condition Involving Skin Barrier Impairment and Allergic Symptoms: Netherton Syndrome
Superficial skin swabs, Stool samples, Saliva samples - Netherton Syndrome
RecruitingAssistance Publique - Hôpitaux de Paris302026-05-262026-06-30
Lymphocyte Phenotype of Autosomal Recessive Congenital Ichthyoses Mutated NIPAL4 (Nipal4-nEDD)
blood sampling - Sezary Syndrome, Ichthyosis, Lamellar
Not yet recruitingAssistance Publique - Hôpitaux de Paris102026-04-012026-03-17
Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome
QRX003 - Netherton Syndrome
Phase 2 / Phase 3RecruitingQuoin Pharmaceuticals162026-03-192026-09-28
Transcutaneous Electrical Acustimulation for IBS-D: A Multicenter Study
Portable stimulator - IBS, Diarrhea Predominant
Not applicableNot yet recruitingFirst People's Hospital of Foshan2002026-03-012026-02-20
Thera-Clean® Microbubbles System in Patients With Skin Diseases
TheraClean - Epidermolysis Bullosa, Ichthyosis
Early Phase 1Enrolling by invitationNorthwestern University202026-01-132026-02-03
Evaluating Whether Intact Fish Skin Graft Can Decrease the Need for Autograft in the Treatment of Deep Partial-Thickness Burns
Intact fish skin graft, autograft - Partial-thickness Burn Wounds
Phase 4Enrolling by invitationKerecis Ltd.652026-01-012026-01-08
Co-Development and Validation of Colonic Symptom Pictograms for Young People
Pictogram comprehension and validation - Constipation - Functional, Abdominal Pain (AP)
Not yet recruitingUniversity of Auckland, New Zealand1202026-01-012026-01-13
Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome
Saccharomyces Boulardii 250 MG, Placebo 250 mg - IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant)
Phase 3RecruitingBiocodex4062025-10-222025-11-18
Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome
QRX003, 4% Lotion - Netherton Syndrome
Phase 2 / Phase 3RecruitingQuoin Pharmaceuticals82025-10-062026-08-31
The Beneficial Effects on the Intestinal Function of a Food Supplement Based on an Extract of Green Tea and a Pool of Probiotics in Subjects With Irritable Bowel Syndrome With Predominance of Constipation
food supplement based on a mixture of green tea extract and a pool of probiotics., Placebo - IBS, Constipation Predominant
Not applicableRecruitingAdamas Biotech S.r.l.642025-07-302025-08-05
Natural History of Sphingosine Phosphate Lyase Insufficiency Syndrome (SPLIS)
no intervention - Sphingosine Phosphate Lyase Insufficiency Syndrome (SPLIS)
RecruitingUniversity of California, San Francisco282025-04-222026-08-04
A Clinical Evaluation of Marula-Derived Ceramide Cream on Skin Barrier Function Enhancement
Apply a cream containing 0.05% marula oil-derived ceramide NPs - Atopic Dermatitis (AD), Psoriasis
Not applicableCompletedShanghai Chicmax Cosmetic Co., Ltd.322025-02-062025-07-15
Natural History of Netherton Syndrome
Netherton Syndrome
TerminatedBoehringer Ingelheim42024-10-092026-06-24
A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725
BCX17725, Placebo - Netherton Syndrome
Phase 1RecruitingBioCryst Pharmaceuticals782024-09-262026-08-27
Efficacy of Injectable Gentamicin in Hereditary Ichthyosis
Gentamicin Injectable Solution - Ichthyosis
Phase 2Not yet recruitingUniversity Hospital, Toulouse262024-09-012024-09-05
Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome
ATR12-351 - Netherton Syndrome
Phase 1CompletedAzitra Inc.62024-06-162026-07-29

Showing 20 of 97. Sign in to see all of them.

Narrower conditions

Ichthyosis Bullosa of Siemens (24)  ·  Netherton Syndrome (22)  ·  Irritable Bowel Syndrome (17)  ·  Ichthyosis Vulgaris (12)  ·  Ichthyosis, Lamellar (7)  ·  Dermatitis, Atopic (6)  ·  Sjogren-Larsson Syndrome (6)  ·  Ichthyosis, X-Linked (5)  ·  Keratoderma, Palmoplantar (5)  ·  Epidermolysis Bullosa (4)  ·  Hyperkeratosis, Epidermolytic (4)  ·  Psoriasis (4)  ·  Albinism (3)  ·  Charcot-Marie-Tooth Disease (3)

Broader conditions

Congenital Abnormalities (97)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (97)  ·  Skin Abnormalities (97)  ·  Skin and Connective Tissue Diseases (97)  ·  Keratosis (96)  ·  Skin Diseases (94)  ·  Infant, Newborn, Diseases (86)  ·  Genetic Diseases, Inborn (85)  ·  Skin Diseases, Genetic (81)  ·  Abnormalities, Multiple (28)  ·  Ichthyosiform Erythroderma, Congenital (28)  ·  Digestive System Diseases (19)  ·  Colonic Diseases (17)  ·  Colonic Diseases, Functional (17)

Interventions

Blood Specimen Collection (3)  ·  Doxorubicin (2)  ·  Trabectedin (2)  ·  Ustekinumab (2)  ·  dupilumab (2)  ·  secukinumab (2)  ·  ADI PEG20 (1)  ·  ADX-629 (1)  ·  Acupuncture Therapy (1)  ·  Adalimumab (1)  ·  Biopsy (1)  ·  Chenodeoxycholic Acid (1)  ·  Curcumin (1)  ·  Data Collection (1)  ·  Diet (1)

Sponsors

Northwestern University (8)  ·  University Hospital, Toulouse (5)  ·  Assistance Publique - Hôpitaux de Paris (4)  ·  Maastricht University Medical Center (4)  ·  Quoin Pharmaceuticals (4)  ·  Children's Hospital of Philadelphia (3)  ·  Daiichi Sankyo (3)  ·  Kerecis Ltd. (3)  ·  Mayo Clinic (3)  ·  Aldeyra Therapeutics, Inc. (2)  ·  Boehringer Ingelheim (2)  ·  Centre Hospitalier Universitaire de Nice (2)  ·  Institut National de la Santé Et de la Recherche Médicale, France (2)  ·  LEO Pharma (2)  ·  National Cancer Institute (NCI) (2)

Countries

United States (51)  ·  France (21)  ·  Netherlands (8)  ·  Germany (6)  ·  Italy (6)  ·  United Kingdom (5)  ·  Australia (4)  ·  Canada (4)  ·  China (4)  ·  Spain (4)  ·  Finland (2)  ·  Israel (2)  ·  Portugal (2)  ·  Russia (2)  ·  Sweden (2)

Top investigators

Amy Paller, MD (4)  ·  Adeline Vanderver, MD (2)  ·  Amy Paller (2)  ·  Antoni Gostynski, MD, PhD (2)  ·  Tony Andrasfay (2)  ·  William B Rizzo, MD (2)  ·  Alain Hovnanian, MD, PhD (1)  ·  Alan Irvine (1)  ·  Albert C Yan, MD (1)  ·  Amy S Paller, MD (1)  ·  Andres Poveda, Ph.M. (1)  ·  Antoni C Gostynski, MD, PhD (1)  ·  Antoni H Gostynski, MD, PhD (1)

Results publications

PMID 11511292, PMID 11912510, PMID 12648223, PMID 14734878, PMID 15238912, PMID 16250204, PMID 18571597, PMID 18948357, PMID 19241467, PMID 19638214, PMID 20083693, PMID 20691689, PMID 22517769, PMID 24102348, PMID 24329107, PMID 24920311, PMID 27144627, PMID 31327218, PMID 32153925, PMID 32342562, PMID 32749716, PMID 34543653, PMID 35088760, PMID 35218370, PMID 35260030, PMID 35663767, PMID 35973183, PMID 36052114, PMID 37170057, PMID 39365895, PMID 40908106, PMID 41637861, PMID 9804339, PMID 9843209

NIH funding

UL1RR024150 (2), 1RC1DK086182 (1), 2008 (1), 2014 (1), 2025 (1), R01AT007137 (1), R01DK054681 (1), R01DK079866 (1), R01HD113778 (1), R21AT003619 (1), U01NS106845 (1), U54NS115052 (1), UL1TR001436 (1)